LiVeritas Biosciences, Inc.

LiVeritas Biosciences, Inc. is a 2020-founded startup based in the United States that focuses on providing quality and timely mass spectrometry data accessible to all drug developers. The company's slogan "Quality and Timely Mass Spectrometry Data Accessible to All Drug Developers" reflects its core mission. LiVeritas Biosciences aims to fast track drug research & development (R&D) processes through mass spectrometry (MS) and digital transformation. The startup offers curated analytical test packages that effectively advance drug candidates in the development pipeline, covering various stages such as drug design optimization, process development, characterization, and accelerating novel drug candidates' path to Investigational New Drug (IND) status. In addition, LiVeritas Biosciences provides partner-centric software solutions that streamline analytical operations, CMC strategies, and drug product knowledge management. The company's expertise is grounded in big biopharma core competencies, and it has a strong focus on milestone-driven outcomes. Although the last known investment details are not available, the company received a Non-Equity Assistance investment on 01 February 2021. LiVeritas Biosciences operates in the AI, Biopharma, Biotechnology, and SaaS industries, portraying its diverse portfolio.